Skip to content

Other product segments

Jornay PM
$104.78M-44.4%
Symproic
$6.07M-54.5%

Similar metrics at other companies

Sphere Entertainment logo
SPHRSphere — Thereafter
$0
Liberty Global logo
LBTYBOther — Thereafter
$0
Marriott Vacations Worldwide logo
VACNon-securitized — Thereafter
$191M-4.5%
Wynn Resorts logo
WYNNEncore Boston Harbor — Thereafter
$3.15B-4.3%
Ford Motor Company logo
FCompany excluding Ford Credit — Thereafter
$13.5B+3.4%
Duke Energy logo
DUKThereafter
$58.98B+4.6%

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.15B+20.4%
Enterprise value$869.67M+2.5%
P/E15.4×-6.4×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept coll:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — thereafter.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s belbuca — thereafter?
Collegium Pharmaceutical, Inc. (COLL) reported belbuca — thereafter of $0 in Q1 2026.
What does belbuca — thereafter mean?
Represents the projected future revenue or financial obligations associated with the Belbuca product line beyond the standard five-year reporting window. This metric helps investors assess the long-term sustainability and terminal value of the product's market lifecycle. It is critical for modeling the tail-end cash flows of specialty pharmaceutical assets.